Background: Canada does not have universal public coverage for prescription drugs, which
leaves an important role for private insurance plans. However, we do not have recent data …

Background Prevalence is reflective of disease incidence and survival, and defined as the
number of patients living with active disease. In diseases such as diffuse large B-cell …

Background Estimation of causal effects of short interpregnancy interval on pregnancy outcomes
may be confounded by time‐varying factors. These confounders should be ascertained …

… Material preparation, data collection and analysis were performed by Basia Rogula and
Talshyn Bolatova. The first draft of the manuscript was written by Shelagh M. Szabo and all …

… The work in this thesis research was conducted and written by Talshyn Bolatova (TB) under
the supervision of Dr. Michael Law. The development of research questions, study design, …

Objective Based on concerns about existing patient-reported outcome measures (PROMs)
for assessing quality of life (QoL) in Duchenne muscular dystrophy (DMD), we describe the …

Objective: The aim of the study was to assess different outcome measures in a cohort of
ambulant boys with Duchenne muscular dystrophy (DMD) over 12 months in order to establish …

Background: Canada lacks universal pharmaceutical coverage (pharmacare). Calls for the
implementation of national pharmacare date back to the introduction of Canadian Medicare …

Many Canadians require prescription drugs to manage their health. In 2021, more than two-thirds
(67%) of Canadians reported taking or being prescribed a medication in the last 12 …

We provide evidence of advantageous selection in the Medigap insurance market and
analyze its sources. Conditional on controls for Medigap prices, those with Medigap spend, on …